# New clinical trials in Australia: 1,482 since Nov 2024

Updated November 9, 2026.

1,482 clinical studies with a site in Australia were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 1,217 have an industry sponsor and 1,156 are recruiting or about to. The newest, NCT07926334, was posted on November 9, 2026: A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer... (Boehringer Ingelheim).

## The full list

New clinical trials with a site in Australia: 1,482 rows for $74.10, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 40 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/country/australia

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 1,482
- Industry sponsored: 1,217
- Recruiting or not yet: 1,156
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 1,482, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07926334 | A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation | Boehringer Ingelheim | Phase 1 | Not yet recruiting | Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | 200 | Australia, Japan, South Korea, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926334) |
| November 6, 2026 | NCT07923097 | Study Designed to Evaluate the Safety, Tolerability, and PK of RAP-219 Formulated as an Long Acting Injectable. | Rapport Therapeutics Inc. | Phase 1 | Recruiting | Epilepsy | 60 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923097) |
| November 6, 2026 | NCT07921576 | Phase 1/2 Study of DS010 in Advanced Cancer Patients With Cachexia | Dartsbio Pharmaceuticals Ltd. | Phase 1/2 | Recruiting | Cancer, Cachexia | 58 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921576) |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Denmark, Germany... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919405) |
| November 5, 2026 | NCT07917780 | A Prospective, Open-label, Randomized, Multicenter Phase-III Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With... | German CLL Study Group | Phase 2 | Recruiting | Richter Transformation | 116 | Australia, Austria, Denmark, Germany, Ireland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917780) |
| November 4, 2026 | NCT07916857 | Comparison of VxWave and Standard Ultrasound Measurements of Blood Vessels in the Arm | Vexev Pty Ltd | Not applicable | Not yet recruiting | Upper Limb Vascular Imaging | 85 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916857) |
| November 4, 2026 | NCT07916727 | Specific and Novel Approaches to Care of Inflammatory Bowel Disease During Pregnancy: the PREGO Study | Austin Health | Not applicable | Recruiting | Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis), Pregnancy | 50 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916727) |
| November 4, 2026 | NCT07915375 | Perceptions and Acceptance of Grafting of Cryopreserved Testicular Tissue | Murdoch Childrens Research Institute | Observational | Not yet recruiting | Fertility, Testicular Tissue Cryopreserved, Fertility Preservation | 105 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915375) |
| November 4, 2026 | NCT07915297 | Safety and Biodistribution of \[68Ga\]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC) | Luminance Biosciences Inc | Phase 1 | Not yet recruiting | Metastatic Breast Cancer | 10 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915297) |
| November 3, 2026 | NCT07913594 | Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma | Olivia Newton-John Cancer Research Institute | Phase 2 | Not yet recruiting | Peripheral T-Cell Lymphoma Refractory | 25 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913594) |
| October 30, 2026 | NCT07908147 | Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study | Olivia Newton-John Cancer Research Institute | Early phase 1 | Not yet recruiting | IDH Wildtype Glioblastoma, Glioblastoma (GBM) | 12 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908147) |
| October 29, 2026 | NCT07905053 | A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of CBT-248 in Healthy Adult Participants | Cibus Therapeutics, Inc. | Phase 1 | Recruiting | Chronic Pancreatitis | 32 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905053) |
| October 29, 2026 | NCT07904689 | A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis | North Immunology Inc. | Phase 1 | Not yet recruiting | Atopic Dermatitis (AD) | 96 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904689) |
| October 29, 2026 | NCT07903779 | Effects of Smartphone Use and Television Viewing on Standardized BP Measurement: The SCREENS-BP Study | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Not applicable | Not yet recruiting | Hypertension | 96 | Australia, Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903779) |
| October 29, 2026 | NCT07903493 | Phase Ia Study of MST-931 in Healthy Adult Subjects | Mabsoft Therapeutics (Shanghai) Co., Ltd. | Phase 1 | Recruiting | Ankylosing Spondylitis (AS) | 32 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903493) |
| October 28, 2026 | NCT07901933 | Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease | Cajal Therapeutics Inc. | Phase 1 | Not yet recruiting | Chronic Kidney Disease, Anemia | 24 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901933) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | Argentina, Australia, Brazil, Canada, China, Czechia, France, Germany, Hungary... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 28, 2026 | NCT07900568 | Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate Asthma | Helixon Biotechnology (Suzhou) Co., Ltd | Phase 1 | Not yet recruiting | Health Adults, Asthma | 40 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900568) |
| October 27, 2026 | NCT07898462 | A Trial of Adjunctive Fludrocortisone (50mcg, 100mcg or Placebo) in Critically Ill Patients With Septic Shock Receiving Hydrocortisone... | The George Institute | Phase 3 | Recruiting | Septic Shock | 2,200 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898462) |
| October 26, 2026 | NCT07894887 | EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C) | Editas Medicine, Inc. | Phase 1/2 | Not yet recruiting | Heterozygous Familial Hypercholesterolemia (HeFH) | 56 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894887) |
| October 23, 2026 | NCT07891533 | Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera | AN2 Therapeutics, Inc | Phase 2 | Not yet recruiting | Polycythemia Vera (SNOMED CT: 109992005) | 75 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891533) |
| October 22, 2026 | NCT07890870 | A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity. | iBio, Inc. | Phase 1 | Not yet recruiting | Obesity & Overweight | 32 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890870) |
| October 22, 2026 | NCT07888686 | Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV)... | Serum Institute of India Pvt. Ltd. | Phase 1/2 | Not yet recruiting | Human Papillomavirus Infection | 72 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888686) |
| October 21, 2026 | NCT07885267 | Safety and Tolerability of AT-0174 in Adults With Advanced Solid Tumors | Antido Therapeutics (Australia) Pty Ltd | Phase 1 | Completed | Advanced Solid Tumor | 26 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885267) |
| October 19, 2026 | NCT07881770 | Semaglutide Health Outcomes and Patient Adherence in Australia | Novo Nordisk A/S | Observational | Not yet recruiting | Overweight, Obesity | 10,000 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881770) |
| October 19, 2026 | NCT07881185 | Artificial Intelligence for Brain MRI Analysis in Epilepsy | Istituto Giannina Gaslini | Observational | Recruiting | Epilepsies | 2,000 | Australia, Belgium, Brazil, Canada, China, Germany, Italy, Mexico, South... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881185) |
| October 16, 2026 | NCT07877155 | To Evaluate the Safety and Efficacy of Hemay5394 in Patients With Mild to Moderate Atopic Dermatitis | Hemay Pharmaceutical PTY. LTD. | Phase 2 | Not yet recruiting | Safety, Efficiency | 90 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877155) |
| October 15, 2026 | NCT07876076 | A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response | Adaxion Therapeutics | Phase 1 | Recruiting | Healthy | 88 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876076) |
| October 15, 2026 | NCT07875673 | A Study to Test New Investigational Drugs (LCFA-01and LC103) for Bacterial Vaginosis (BV) Treatment | Massachusetts General Hospital | Phase 1 | Not yet recruiting | Bacterial Vaginosis | 280 | Australia, South Africa | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875673) |
| October 15, 2026 | NCT07875309 | An Online Tailored Cognitive Therapy-Based Intervention for Depression in Multiple Sclerosis: ACTION-MS Online | University of Melbourne | Not applicable | Not yet recruiting | Depression and Anxiety Symptoms, Multiple Sclerosis | 240 | Australia, Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875309) |
| October 14, 2026 | NCT07874139 | Prospective Study on Antimicrobial RESIstance in Chronic Pulmonary DiseasE | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Observational | Recruiting | Chronic Lung Diseases | 683 | Albania, Australia, Belgium, Brazil, Canada, China, Croatia, Czechia, Denmark... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874139) |
| October 14, 2026 | NCT07873671 | A Trial of RLX-2508-102 in Healthy Volunteers | Atridia Pty Ltd. | Early phase 1 | Not yet recruiting | Influenza | 101 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873671) |
| October 14, 2026 | NCT07873450 | SumMET: Study of \[225Ac\]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET | Full-Life Technologies UK Limited | Phase 1/2 | Recruiting | Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer, Cholangiocarcinoma | 208 | Australia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873450) |
| October 14, 2026 | NCT07873229 | DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine | Eccogene | Phase 1 | Not yet recruiting | Steatohepatitis, Nonalcoholic, Osteo Arthritis | 40 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873229) |
| October 13, 2026 | NCT07871214 | A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage... | Bristol-Myers Squibb | Phase 2 | Not yet recruiting | Early-Stage Non-Small Cell Lung Cancer | 80 | Australia, Canada, China, France, Germany, Italy, Japan, Poland, Romania, South... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871214) |
| October 13, 2026 | NCT07870343 | Healthcare and Community Service Utilisation in Older Survivors of Critical Illness | Monash University | Observational | Not yet recruiting | Critical Illness | 30 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870343) |
| October 13, 2026 | NCT07869940 | First-in-human Trial of RBD2080 in Healthy Participants | Suzhou Ribo Life Science Co. Ltd. | Phase 1 | Recruiting | Healthy | 24 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869940) |
| October 9, 2026 | NCT07869225 | A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers | Equillium | Phase 1 | Not yet recruiting | Ulcerative Colitis | 70 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869225) |
| October 8, 2026 | NCT07866300 | A Study of KMV002 in Patients With mAPMR Prostate Cancer | Chimivac INC | Phase 1 | Not yet recruiting | Prostate Cancer Metastatic Castration-Resistant | 24 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07866300) |
| October 8, 2026 | NCT07865442 | First in Human Study of ALT-01 in Healthy Participants | Altis Medicines, Inc | Phase 1 | Not yet recruiting | Autoimmune Disease | 50 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07865442) |
| October 7, 2026 | NCT07864350 | Stopping Strep Throat With Antibodies in Healthy Adults. | Murdoch Childrens Research Institute | Phase 1 | Not yet recruiting | Streptococcal Pharyngitis | 60 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864350) |
| October 7, 2026 | NCT07864311 | A Phase 1 Study of VELA-101 in Adult Participants | Ursa Medicines | Phase 1 | Not yet recruiting | Healthy Participants, Hyperlipidemia | 60 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864311) |
| October 6, 2026 | NCT07861100 | A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Cardiovascular Risk, Obesity | 8,500 | Argentina, Australia, Brazil, Bulgaria, Canada, China, Czechia, Denmark... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861100) |
| October 5, 2026 | NCT07858526 | Optimised Dalbavancin Dosing for Serious Gram-Positive Bacterial Infections | Kirby Institute | Observational | Not yet recruiting | Serious Gram-Positive Bacterial Infections | 50 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858526) |
| October 5, 2026 | NCT07858019 | A Study to Evaluate COR-2003 as Monotherapy and Co-Administered With COR-1004 in Adult Volunteers | Corsera Health | Phase 1 | Not yet recruiting | Otherwise Healthy Individuals With Systolic Blood Pressure (SBP) From 110 to 139 mmHg and Low-density Lipoprotein... | 108 | Australia, New Zealand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858019) |
| October 5, 2026 | NCT07857473 | A Study to Investigate the Safety and Efficacy of TE-8105 in Overweight or Obesity Participants | Immunwork, Inc. | Phase 2 | Not yet recruiting | Overweight and Obesity | 204 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857473) |
| October 2, 2026 | NCT07856095 | A Study of a Device That Helps Place Dialysis Needles | X9, Inc. | Not applicable | Not yet recruiting | Dialysis, Cannulation, Vascular Access | 35 | Australia, New Zealand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856095) |
| October 2, 2026 | NCT07855510 | A Clinical Trial of V175 and V175A in Healthy Adults | Merck Sharp & Dohme LLC | Phase 1 | Recruiting | Lower Respiratory Tract Infection | 564 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855510) |
| October 1, 2026 | NCT07852208 | A Study of Intranasal LMN-1001 in Healthy Adults | Lumen Bioscience, Inc. | Phase 1 | Not yet recruiting | Viral Infections | 36 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07852208) |
| October 1, 2026 | NCT07851025 | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced... | AstraZeneca | Phase 3 | Recruiting | Epithelial Ovarian Cancer | 950 | Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Colombia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851025) |
| September 30, 2026 | NCT07850466 | TRPTI Metabolic and GLP-1 Pharmacodynamic Study | RDC Clinical Pty Ltd | Phase 4 | Not yet recruiting | Overweight , Obesity | 20 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850466) |
| September 30, 2026 | NCT07850310 | A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001) | Merck Sharp & Dohme LLC | Phase 1 | Recruiting | Psoriasis, Healthy | 132 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850310) |
| September 30, 2026 | NCT07849231 | A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms | Damora Therapeutics | Phase 1 | Recruiting | Myeloproliferative Neoplasms (MPNs) | 250 | Australia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07849231) |
| September 29, 2026 | NCT07846865 | Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea | Woolcock Institute of Medical Research | Phase 2/3 | Not yet recruiting | Sleep Apnoea, Obesity & Overweight, Sleep Apnea Syndrome, Obstructive | 256 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07846865) |
| September 29, 2026 | NCT07845500 | A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity | 660 | Australia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845500) |
| September 28, 2026 | NCT07845045 | The Relationship Between Lower Abdominal Temperature and Pain in Women With Dysmenorrhoea During Acupuncture | HUEI-WEN LIAU | Not applicable | Completed | Dysmenorrhoea | 30 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845045) |
| September 28, 2026 | NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | Boehringer Ingelheim | Phase 1/2 | Recruiting | Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer | 55 | Australia, Belgium, China, France, Germany, Japan, Netherlands, Poland, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843940) |
| September 24, 2026 | NCT07840001 | Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma | Peter MacCallum Cancer Centre, Australia | Phase 2 | Not yet recruiting | Locally Advanced Clear Cell Renal Cell Carcinoma | 30 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840001) |
| September 23, 2026 | NCT07836452 | A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants | City Therapeutics | Phase 1 | Recruiting | Stargardt Disease 1, STGD1, Healthy Volunteers | 48 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836452) |
| September 22, 2026 | NCT07834229 | Telerehabilitation Versus Clinic-Based Rehabilitation for Functional Recovery Following Primary Total Knee Arthroplasty | The University of Western Australia | Not applicable | Completed | Total Knee Arthroplasty Recovery, Total Knee Replacement, Total Knee Arthroplasty\\(TKA\\), Knee Arthritis... | 108 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07834229) |
| September 21, 2026 | NCT07832292 | A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer | Janssen Research & Development, LLC | Phase 2 | Recruiting | Prostatic Neoplasms | 100 | Australia, China, Japan, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832292) |
| September 21, 2026 | NCT07831226 | Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years | Guangzhou Patronus Biotech Co., Ltd. | Phase 1 | Not yet recruiting | Malaria Vaccine | 72 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831226) |
| September 21, 2026 | NCT07830732 | A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A | Novo Nordisk A/S | Phase 3 | Recruiting | Haemophilia A | 84 | Argentina, Australia, Brazil, Canada, Denmark, France, Germany, Greece, India... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830732) |
| September 21, 2026 | NCT07830719 | Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP | Novartis Pharmaceuticals | Phase 2 | Recruiting | Coronary Artery Disease | 180 | Australia, Germany, Japan, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830719) |
| September 21, 2026 | NCT07830108 | ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With... | Starship Child Health, Te Toka Tumai Auckland | Phase 3 | Not yet recruiting | Rheumatic Fever, Rheumatic Heart Disease in Children, Acute Rheumatic Fever, Rheumatic Heart Disease | 600 | Australia, New Zealand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830108) |
| September 21, 2026 | NCT07829302 | VV-14299 and VV-14300 for the Treatment of Type 1 Diabetes | Kriya Therapeutics, Inc. | Phase 1/2 | Recruiting | Type 1 Diabetes Mellitus | 29 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829302) |
| September 18, 2026 | NCT07827144 | A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours) | AIMEDBIO | Phase 1 | Recruiting | Solid Tumours | 86 | Australia, France, Japan, South Korea, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827144) |
| September 17, 2026 | NCT07826689 | A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis | Progentos Therapeutics | Phase 1/2 | Recruiting | Multiple Sclerosis | 160 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07826689) |
| September 16, 2026 | NCT07822022 | Implementing Improved Blood Pressure Measurement in General Practice: A Multisite Implementation Trial Using Automated Office Blood... | Menzies Institute for Medical Research | Not applicable | Not yet recruiting | Hypertension, Cardiovascular Diseases (CVD), Vascular Diseases | 6,000 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822022) |
| September 14, 2026 | NCT07818330 | A Repeat Dose Study of the Dexmedetomidine Transdermal System in Healthy Subjects | Teikoku Pharma USA, Inc. | Phase 1 | Terminated | Healthy Subjects | 8 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818330) |
| September 14, 2026 | NCT07817459 | Dogs Offering Guidance: Therapeutic Observation for Reducing Examination Anxiety (DOGTOR). | La Trobe University | Not applicable | Recruiting | Examination Phobia | 22 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817459) |
| September 14, 2026 | NCT07816666 | Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer | AstraZeneca | Phase 3 | Recruiting | Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer... | 600 | Australia, Brazil, Canada, China, Germany, India, Italy, Japan, South Korea... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816666) |
| September 11, 2026 | NCT07816172 | Effects of Macanity on Urinary Health in Males With Lower Urinary Tract Symptoms | RDC Clinical Pty Ltd | Phase 2 | Not yet recruiting | Lower Urinary Tract Symptoms (LUTS) | 200 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816172) |
| September 11, 2026 | NCT07815249 | Speech Therapy for Children With Rare Genetic Conditions and Childhood Apraxia of Speech | Murdoch Childrens Research Institute | Not applicable | Recruiting | Childhood Apraxia of Speech, Genetic Condition | 20 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815249) |
| September 10, 2026 | NCT07813013 | Right Colon Enema to Improve Bowel Preparation Quality During Colonoscopy | Westmead Hospital | Not applicable | Not yet recruiting | Colonic Polyps, Colorectal Neoplasms, Colonoscopy, Bowel Preparation Quality | 320 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07813013) |
| September 9, 2026 | NCT07810777 | PRA-216 Atopic Dermatitis Safety and Efficacy Study | Prana Therapies Inc | Phase 2 | Recruiting | Atopic Dermatitis (AD) | 39 | Australia, New Zealand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07810777) |
| September 9, 2026 | NCT07810010 | Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age... | Sanofi | Phase 2 | Recruiting | Respiratory Syncytial Virus, Human Metapneumovirus, Healthy Volunteers | 8,000 | Australia, United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07810010) |
| September 4, 2026 | NCT07805369 | A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer | DEM BioPharma, Inc. | Phase 1 | Recruiting | Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer | 60 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805369) |
| September 4, 2026 | NCT07804628 | A Single and Multiple Dose Study to Evaluate the Safety and Effects of Inhaled ICF001 Dry Powder in Healthy Participants | VIVID CLINICAL SERVICES PTY LTD | Phase 1 | Not yet recruiting | Healthy Volunteers | 72 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804628) |
| September 3, 2026 | NCT07802704 | A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) \[EMBOLD Prostate-302\] | GlaxoSmithKline | Phase 3 | Recruiting | Neoplasms, Prostate | 684 | Australia, Canada, Japan, South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802704) |
| September 3, 2026 | NCT07801508 | A Study of \[68Ga\]Ga-DWJ155 in Adult Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer, Triple-negative Breast Cancer, Advanced Non-small... | 66 | Australia, Japan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801508) |
| September 1, 2026 | NCT07798609 | A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in Adults With FSHD | Soufflé Therapeutics, Inc. | Phase 1/2 | Recruiting | Facioscapulohumeral Muscular Dystrophy (FSHD) | 90 | Australia, New Zealand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07798609) |
| September 1, 2026 | NCT07796672 | Feasibility Study of Blood Biomarker Identification in Cervical Cancer | Queensland Centre for Gynaecological Cancer | Observational | Recruiting | Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma | 100 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796672) |
| August 28, 2026 | NCT07791797 | Supplementation Absorption Comparison | RDC Clinical Pty Ltd | Phase 4 | Recruiting | Healthy Volunteer | 160 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791797) |
| August 28, 2026 | NCT07789483 | An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy | Alexion Pharmaceuticals, Inc. | Phase 3 | Not yet recruiting | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 1,180 | Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789483) |
| August 27, 2026 | NCT07790601 | Swabs in Screening for HPV (SWISH) | Kirby Institute | Not applicable | Not yet recruiting | Anal Cancer, Human Papilloma Virus (HPV) | 700 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07790601) |
| August 27, 2026 | NCT07789782 | Comparison of a New Non-invasive Device With the Invasive Gold-standard Investigation to Assess Function of the Large Bowel in Children | Murdoch Childrens Research Institute | Not applicable | Not yet recruiting | Bowel Dysfunction, Dysmotility, Hirschsprung Disease, Anorectal Malformations, Constipation, Functional Constipation... | 50 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789782) |
| August 27, 2026 | NCT07789015 | A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Idiopathic Inflammatory Myopathies | 270 | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789015) |
| August 26, 2026 | NCT07788807 | A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the... | Surmount Services, Inc. | Phase 1 | Recruiting | Healthy Subjects | 18 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07788807) |
| August 26, 2026 | NCT07788014 | A Phase 1 Study of Single and Multiple Ascending Doses of GV-100 | Gilva Therapeutics Inc. | Phase 1 | Recruiting | ADPKD (Autosomal Dominant Polycystic Kidney Disease) | 80 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07788014) |
| August 26, 2026 | NCT07787962 | Follow-up of a Randomised Controlled Study of Surgical Peri-implantitis Treatment | The University of Western Australia | Observational | Not yet recruiting | Success, Dental Implant Survival Rate | 40 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07787962) |
| August 25, 2026 | NCT07785193 | A Study of Subcutaneous FL115 Monotherapy in Participants With Advanced Solid Tumors | Suzhou Forlong Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Advanced Solid Tumours | 29 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07785193) |
| August 25, 2026 | NCT07784725 | A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2... | AstraZeneca | Phase 3 | Recruiting | Obesity or Overweight | 2,500 | Argentina, Australia, Brazil, Bulgaria, Canada, China, Czechia, France... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784725) |
| August 25, 2026 | NCT07784270 | A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight | AstraZeneca | Phase 3 | Recruiting | Obesity or Overweight, Diabetes Mellitus, Type 2 | 1,500 | Argentina, Australia, Canada, Chile, China, Germany, Hungary, India, Japan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784270) |
| August 24, 2026 | NCT07782957 | A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis... | GlaxoSmithKline | Phase 3 | Recruiting | Nasal Polyps | 218 | Australia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782957) |
| August 24, 2026 | NCT07781657 | Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease | Hoffmann-La Roche | Phase 2 | Recruiting | Alzheimer's Disease | 450 | Australia, France, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781657) |
| August 24, 2026 | NCT07781137 | Analysis of Long-term Outcomes of Endoscopic Resection of Duodenal and Ampullary Mucosal and Submucosal Lesions | Western Sydney Local Health District | Observational | Recruiting | Duodenal Adenoma, Duodenal Carcinoma, Papillary Adenoma, Papillary Adenocarcinoma, Endoscopic Mucosal Resection | 1,000 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781137) |
| August 24, 2026 | NCT07780786 | Non-invasive Saphenous Nerve Stimulation Therapy for Overactive Bladder | NinaMED Pty Ltd | Phase 3 | Not yet recruiting | Overactive Bladder (OAB) | 290 | Australia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780786) |
| August 21, 2026 | NCT07778446 | A Study to Test CRT-402 in Refractory Autoimmune Disease | Myeloid Therapeutics | Phase 1/2 | Recruiting | Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Scleroderma, Myositis | 34 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778446) |
| August 21, 2026 | NCT07778316 | Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) | Amgen | Phase 3 | Recruiting | Small Cell Lung Cancer | 400 | Australia, China, Japan, Switzerland, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778316) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| AstraZeneca | 61 | October 1, 2026 |
| Merck Sharp & Dohme LLC | 41 | October 2, 2026 |
| Novartis Pharmaceuticals | 36 | September 21, 2026 |
| GlaxoSmithKline | 30 | September 3, 2026 |
| Eli Lilly and Company | 26 | October 28, 2026 |
| Sanofi | 26 | September 9, 2026 |
| Boehringer Ingelheim | 25 | November 9, 2026 |
| Janssen Research & Development, LLC | 25 | September 21, 2026 |
| Bristol-Myers Squibb | 24 | October 13, 2026 |
| Hoffmann-La Roche | 24 | August 24, 2026 |
| Murdoch Childrens Research Institute | 23 | November 4, 2026 |
| Novo Nordisk A/S | 22 | November 5, 2026 |
| Pfizer | 22 | September 29, 2026 |
| Amgen | 21 | August 21, 2026 |
| BeOne Medicines | 20 | August 4, 2026 |
| RDC Clinical Pty Ltd | 16 | September 30, 2026 |
| AbbVie | 16 | August 19, 2026 |
| BioNTech SE | 14 | March 6, 2026 |
| Monash University | 12 | October 13, 2026 |
| Peter MacCallum Cancer Centre, Australia | 12 | September 24, 2026 |

## Conditions

| Condition group | New trials | Latest |
| --- | --- | --- |
| [Carcinoma, Non-Small-Cell Lung](https://specstream.ai/data/clinical-trials/condition/carcinoma-non-small-cell-lung) | 75 | October 14, 2026 |
| [Obesity](https://specstream.ai/data/clinical-trials/condition/obesity) | 66 | November 5, 2026 |
| [Overweight](https://specstream.ai/data/clinical-trials/condition/overweight) | 48 | October 28, 2026 |
| [Neoplasms](https://specstream.ai/data/clinical-trials/condition/neoplasms) | 46 | November 6, 2026 |
| [Breast Neoplasms](https://specstream.ai/data/clinical-trials/condition/breast-neoplasms) | 42 | November 4, 2026 |
| [Colorectal Neoplasms](https://specstream.ai/data/clinical-trials/condition/colorectal-neoplasms) | 39 | October 14, 2026 |
| [Prostatic Neoplasms](https://specstream.ai/data/clinical-trials/condition/prostatic-neoplasms) | 35 | September 21, 2026 |
| [Neoplasm Metastasis](https://specstream.ai/data/clinical-trials/condition/neoplasm-metastasis) | 31 | August 4, 2026 |
| [Lung Neoplasms](https://specstream.ai/data/clinical-trials/condition/lung-neoplasms) | 26 | June 4, 2026 |
| [Ovarian Neoplasms](https://specstream.ai/data/clinical-trials/condition/ovarian-neoplasms) | 25 | September 14, 2026 |
| [Multiple Myeloma](https://specstream.ai/data/clinical-trials/condition/multiple-myeloma) | 25 | August 14, 2026 |
| [Diabetes Mellitus, Type 2](https://specstream.ai/data/clinical-trials/condition/diabetes-mellitus-type-2) | 23 | October 28, 2026 |
| [Recurrence](https://specstream.ai/data/clinical-trials/condition/recurrence) | 22 | November 3, 2026 |
| [Alzheimer Disease](https://specstream.ai/data/clinical-trials/condition/alzheimer-disease) | 22 | August 24, 2026 |
| [Melanoma](https://specstream.ai/data/clinical-trials/condition/melanoma) | 21 | August 6, 2026 |
| [Small Cell Lung Carcinoma](https://specstream.ai/data/clinical-trials/condition/small-cell-lung-carcinoma) | 20 | September 28, 2026 |
| [Endometrial Neoplasms](https://specstream.ai/data/clinical-trials/condition/endometrial-neoplasms) | 18 | June 3, 2026 |
| [Renal Insufficiency, Chronic](https://specstream.ai/data/clinical-trials/condition/renal-insufficiency-chronic) | 17 | October 28, 2026 |
| [Stomach Neoplasms](https://specstream.ai/data/clinical-trials/condition/stomach-neoplasms) | 17 | September 3, 2026 |
| [Pancreatic Neoplasms](https://specstream.ai/data/clinical-trials/condition/pancreatic-neoplasms) | 17 | June 12, 2026 |
| [Cardiovascular Diseases](https://specstream.ai/data/clinical-trials/condition/cardiovascular-diseases) | 16 | October 28, 2026 |
| [Colitis, Ulcerative](https://specstream.ai/data/clinical-trials/condition/colitis-ulcerative) | 15 | November 4, 2026 |
| [Lupus Erythematosus, Systemic](https://specstream.ai/data/clinical-trials/condition/lupus-erythematosus-systemic) | 15 | August 21, 2026 |
| Lymphoma, Non-Hodgkin | 15 | May 27, 2026 |
| [Hypertension](https://specstream.ai/data/clinical-trials/condition/hypertension) | 14 | November 5, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 366 | November 5, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 354 | November 9, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 247 | November 5, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 180 | November 4, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 154 | November 6, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 90 | November 4, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 46 | September 29, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 25 | September 30, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 20 | October 30, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).